While FDA held up Sanofi’s diet drug Rimonabant(Acomplia/Zimulti),the Merck’s MK-0364(Taranbant) is currently in phase-3 which is as effective for weight loss as rimonabant having some side effects.
The interim results of phase-3 trial of Taranabant have not been reported by the Merck.These results could be different from the anecdotal report. In the trial it was found that the weight loss pill was well tolerated in extensive phase-2.The Merck is looking forward FDA approval for it next year.
Pfizer, which also contains CB-1 receptor antagonist in phase-3 trials has not moved forward with a name which is known as CP-945598.
In june-2007 there will be a meeting of FDA advisory panel on rimonabant about the safety issues of drugs which affect receptors in the brain. Merck and Pfizer are waiting for the meeting.
No comments:
Post a Comment